READ: Featured Drug Insights: December 2024 - Prime Therapeutics
READ: Featured Drug Insights: December 2024
Your source for all Prime Therapeutics' December 2024 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for December 2024 will keep you informed on what’s trending now.
Released December 30, 2024
A review of newly approved specialty drugs, recent drug launches and new indications in the last month, this month includes zanidatamab-hrii (Ziihera), acoramidis (Attruby), zenocutuzumab-zbco (Bizengri) and more.
An overview of clinical insights’ trending topics and timely drug information highlights, this month discusses how shortages of stimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD) continue to be reported.
Released December 17, 2024
Expert Clinical Network Insights: December 2024
Committed to keeping you informed on the latest specialty drug insights from leading experts, this newsletter features marstacimab-hncq (Hympavzi).
FDA Decisions Expected for January 2025
A breakdown of FDA decisions expected of new drugs expected to hit the market. This edition covers bentracimab, vanzacaftor/tezacaftor/deutivacaftor (vanza triple), trastuzumab (TX05) and more.
Released December 13, 2024
Providing a clinical deep dive into a select high cost drug in the pipeline. This month’s profile features the proposed indications of remestemcel-L Intravenous (IV).
Featuring commentary by Simone Ndujiuba on developments in the oncology space, this installment covers how scientists have made remarkable progress in understanding the thousands of genes inside our cells and the link they may have to cancer.
Released December 12, 2024
A monthly report of the most notable drugs that may significantly affect the populations we serve, drug highlights this month are tirzepatide (Zepbound) and prademagene zamikeracel.
Endo is expanding its previously announced July 2024 voluntary recall of Clonazepam Orally Disintegrating Tablets (schedule IV controlled substance) due to potential product carton strength mislabeling. Endo’s ongoing investigation has identified the possibility that the clonazepam product lot numbers listed at the link below could contain cartons printed with the incorrect strength and National Drug Code (NDC) due to an error by a third-party packager.
All brand names are property of their respective owners.